These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 6417770)

  • 21. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
    Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
    Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of pulmonary Pseudomonas aeruginosa infection in cystic fibrosis with cefsulodin.
    Møller NE; Koch C; Vesterhauge S; Jensen K
    Scand J Infect Dis; 1982; 14(3):207-11. PubMed ID: 6815787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Ansorg R; Müller KD; Wiora J
    Chemotherapy; 1990; 36(3):222-9. PubMed ID: 2110878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
    Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
    Mintz L; Drew WL
    Antimicrob Agents Chemother; 1981 Feb; 19(2):332-4. PubMed ID: 6289731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M; Müller I; Reinhardt D
    Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
    Hodson ME; Gallagher CG; Govan JR
    Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.
    Pedersen SS; Koch C; Høiby N; Rosendal K
    J Antimicrob Chemother; 1986 Apr; 17(4):505-16. PubMed ID: 3086274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H
    Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
    Massoni-Cristante S; Loiez C; Adriensen B; Husson MO
    Pathol Biol (Paris); 2003 Apr; 51(3):135-42. PubMed ID: 12781793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Stenvang Pedersen S; Pressler T; Pedersen M; Høiby N; Friis-Møller A; Koch C
    Scand J Infect Dis; 1986; 18(2):133-7. PubMed ID: 3518048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
    Gold R; Jin E; Levison H; Isles A; Fleming PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():331-6. PubMed ID: 6352638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.
    Szaff M; Høiby N; Flensborg EW
    Acta Paediatr Scand; 1983 Sep; 72(5):651-7. PubMed ID: 6637463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.